EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Faron Pharmaceuticals Oy's Enterprise Value is €111.14 Mil.
Faron Pharmaceuticals Oy's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-18.14 Mil. Therefore, Faron Pharmaceuticals Oy's EV-to-FCF for today is -6.13.
The historical rank and industry rank for Faron Pharmaceuticals Oy's EV-to-FCF or its related term are showing as below:
FRA:4FR'
s EV-to-FCF Range Over the Past 10 Years
Min: -25.13 Med: -6.93 Max: -0.6
Current: -6.14
During the past 13 years, the highest EV-to-FCF of Faron Pharmaceuticals Oy was -0.60. The lowest was -25.13. And the median was -6.93.
FRA:4FR's EV-to-FCF is ranked worse than 100% of 330
companies
in the Biotechnology industry
Industry Median: 16.3
vs FRA:4FR: -6.14
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Faron Pharmaceuticals Oy (FRA:4FR) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Faron Pharmaceuticals Oy's PE Ratio (TTM) for today is calculated as:
Faron Pharmaceuticals Oy's share price for today is €0.512.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Faron Pharmaceuticals Oy's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.221.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Faron Pharmaceuticals Oy EV-to-FCF Related Terms
Faron Pharmaceuticals Oy EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Faron Pharmaceuticals Oy's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Faron Pharmaceuticals Oy EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Faron Pharmaceuticals Oy's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Faron Pharmaceuticals Oy's EV-to-FCF falls into.
Faron Pharmaceuticals Oy's current Enterprise Value is €111.14 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Faron Pharmaceuticals Oy's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-18.14 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Faron Pharmaceuticals Oy (FRA:4FR) has a EV-to-FCF of -6.13 as of Jul. 06, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Faron Pharmaceuticals Oy and its competitors. According to the industry distribution chart, Faron Pharmaceuticals Oy ranks #999999 out of 330 companies in the Biotechnology industry.
Is Faron Pharmaceuticals Oy's EV-to-FCF too high?
Faron Pharmaceuticals Oy's current EV-to-FCF is -6.13. Based on the distribution chart, Faron Pharmaceuticals Oy ranks #999999 out of 330 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Faron Pharmaceuticals Oy has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Faron Pharmaceuticals Oy's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Faron Pharmaceuticals Oy ranks #999999 out of 330 companies for EV-to-FCF. This places Faron Pharmaceuticals Oy in the lower half of its industry. The industry median EV-to-FCF is 16.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.30, based on 330 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Faron Pharmaceuticals Oy and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Faron Pharmaceuticals Oy's current EV-to-FCF is -6.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Faron Pharmaceuticals Oy stock overvalued right now?
Faron Pharmaceuticals Oy (FRA:4FR) has a current EV-to-FCF of -6.13. The current EV-to-FCF is -6.13. Faron Pharmaceuticals Oy's overall GF Score™ is 21/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Faron Pharmaceuticals Oy (FRA:4FR), the current EV-to-FCF is -6.13 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company. The company has one operating and reportable segment. The Group has a pipeline based on the receptors involved in the regulation of immune response in oncology, organ damage, and bone marrow regeneration. Faron is a late clinical stage drug discovery and development Group. The company includes Bexmarilimab in its pipeline. Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and improve clinical outcomes by targeting myeloid cell function in the microenvironment and igniting the immune system against cancer.
21GF Score
Get the complete analysis for FRA:4FR
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4FR has been successfully added to your 
